Drug-Resistant Candida auris Global Threat
Analysis based on 9 articles · First reported Dec 31, 2025 · Last updated Dec 31, 2025
The warning about drug-resistant Candida auris could negatively impact pharmaceutical and biotechnology companies involved in antifungal drug development, as existing treatments are becoming ineffective. Healthcare providers, particularly those in nations/countries with rising infection rates like the United Kingdom, may face increased operational costs and strain on resources.
Scientists have issued a global health threat warning about Candida auris, a drug-resistant fungus that causes severe illness and spreads rapidly in healthcare settings. With a mortality rate exceeding 50%, and up to 72% in some cases, Candida auris is particularly dangerous for individuals with compromised immune systems. First identified in Japan in 2009, it was declared a public health threat in India in 2014 and has since been found worldwide. The fungus develops drug resistance by transforming its growth form, adhering to human skin, and expelling antifungal medications. Rohini Manuel of the United Kingdom — UK Health Security Agency noted rising rates in England, with the United Kingdom — UK Health Security Agency and United Kingdom — National Health Service working to investigate and limit its spread.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard